Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 14/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552312 | 0.86 | MAPK1 (0.79) | ACLYMAPK1MEN1KMT2AGPR55 | |
| SCHEMBL22000209 | 0.81 | ACLY (1.00) | ACLYMEN1KMT2AGPR55 | |
| SCHEMBL15480545 | 0.77 | ACLY (0.74) | ACLYMAPK1HDAC1 | |
| SCHEMBL28274067 | 0.76 | ALDH1A1 (0.64) | ACLYHDAC1 | |
| SCHEMBL28275186 | 0.76 | ACLY (0.67) | ACLYMEN1KMT2A | |
| SCHEMBL21999492 | 0.76 | ACLY (1.00) | ACLYMEN1KMT2AHDAC1 | |
| SCHEMBL3557116 | 0.75 | MEN1 (0.49) | MAPK1MEN1KMT2AGPR55IKBKB | |
| SCHEMBL3554420 | 0.75 | ALDH1A1 (0.56) | MEN1KMT2AGPR55IKBKB | |
| SCHEMBL22000149 | 0.75 | ACLY (1.00) | ACLYHDAC1 | |
| SCHEMBL3563809 | 0.74 | MEN1 (0.62) | MEN1KMT2AGPR55HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | ACLY 586/4885MAPK1 667/4885MEN1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.